1. Home
  2. CBIO vs NGS Comparison

CBIO vs NGS Comparison

Compare CBIO & NGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CBIO
  • NGS
  • Stock Information
  • Founded
  • CBIO 2003
  • NGS 1998
  • Country
  • CBIO United States
  • NGS United States
  • Employees
  • CBIO N/A
  • NGS N/A
  • Industry
  • CBIO
  • NGS Oilfield Services/Equipment
  • Sector
  • CBIO
  • NGS Energy
  • Exchange
  • CBIO Nasdaq
  • NGS Nasdaq
  • Market Cap
  • CBIO 308.0M
  • NGS 305.2M
  • IPO Year
  • CBIO N/A
  • NGS 2002
  • Fundamental
  • Price
  • CBIO $14.29
  • NGS $26.20
  • Analyst Decision
  • CBIO Strong Buy
  • NGS Strong Buy
  • Analyst Count
  • CBIO 5
  • NGS 2
  • Target Price
  • CBIO $25.60
  • NGS $32.50
  • AVG Volume (30 Days)
  • CBIO 98.3K
  • NGS 58.3K
  • Earning Date
  • CBIO 07-31-2025
  • NGS 08-11-2025
  • Dividend Yield
  • CBIO N/A
  • NGS 1.53%
  • EPS Growth
  • CBIO N/A
  • NGS 33.85
  • EPS
  • CBIO N/A
  • NGS 1.42
  • Revenue
  • CBIO N/A
  • NGS $164,109,000.00
  • Revenue This Year
  • CBIO N/A
  • NGS $9.75
  • Revenue Next Year
  • CBIO N/A
  • NGS $14.27
  • P/E Ratio
  • CBIO N/A
  • NGS $18.41
  • Revenue Growth
  • CBIO N/A
  • NGS 14.77
  • 52 Week Low
  • CBIO $10.83
  • NGS $16.73
  • 52 Week High
  • CBIO $21.40
  • NGS $29.74
  • Technical
  • Relative Strength Index (RSI)
  • CBIO 52.92
  • NGS 57.40
  • Support Level
  • CBIO $13.50
  • NGS $25.05
  • Resistance Level
  • CBIO $16.00
  • NGS $26.54
  • Average True Range (ATR)
  • CBIO 0.79
  • NGS 1.08
  • MACD
  • CBIO 0.16
  • NGS 0.13
  • Stochastic Oscillator
  • CBIO 39.68
  • NGS 81.67

About CBIO Crescent Biopharma Inc. Common Stock

Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent believes CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. Crescent is advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.

About NGS Natural Gas Services Group Inc.

Natural Gas Services Group Inc provides natural gas compression equipment and services to the energy industry. The company manufactures, fabricates, rents, sells, and maintains natural gas compressors and flare systems for oil and natural gas production and plant facilities. Its operating units include Rental, Sales, and Aftermarket services. The company generates the majority of its revenue by renting out low- to medium-horsepower compression equipment to natural gas production companies in unconventional oil and gas regions of the United States.

Share on Social Networks: